NK Cell Receptor Biology: Activating/Inhibitory Balance and Cytotoxic Mechanisms
Natural killer cells (NK; innate lymphoid cells; ~5–15% peripheral blood lymphocytes; large granular lymphocytes; CD56+CD3−; no MHC restriction; kill MHC-I-low (missing self) + stress ligand-expressing (induced self) targets; NK cell subsets: CD56brightCD16lo (cytokine producers; IFN-γ/TNFα; tissue-resident); CD56dimCD16hi (cytotoxic; peripheral blood; ADCC); NK education/licensing (self-MHC-I recognition by inhibitory KIRs → educated NK; MHC-I low tumour → missing self → NK activated)); Activating receptors: NKG2D (KLRK1; homodimer; DAP10 (YINM → PI3K) + DAP12 (ITAM → ZAP70) co-receptors; ligands: MICA/MICB + ULBP1-6 (human; stress-induced by oxidative stress/DNA damage/HSPs); NKG2D downstream: PI3K→Akt, VAV1→Rac1→actin polarisation, ZAP70→LAT→PLCγ→Ca2+); NKp46/NCR1 (natural cytotoxicity receptor; ITAM; viral HA binding; DAP12); NKp30/NCR3 (B7-H6/BAG6 ligand; tumour); NKp44/NCR2 (viral; ITAM); CD16/FcγRIIIA (ADCC; IgG-coated targets; Syk/ZAP70; trastuzumab/rituximab ADCC); Inhibitory receptors: NKG2A/CD94 (heterodimer NKG2A-CD94; ITIM; ligand HLA-E/MHC-Ib; tumour HLA-E expression → NKG2A → SHIP1/SHP1 → VAV1 ↓ → NK inhibition); KIR2DL/3DL (killer Ig-like receptor; ITIM; HLA-A/B/C; MHC-I expression → NK inhibition (missing self)); Cytotoxicity (immunological synapse: actin polymerisation; MTOC polarisation; lytic granules: perforin (PFN1; Cys-rich; multimerisation; membrane pore; Ca2+-dependent; Cys73-Cys104 disulphide; MACPF domain; TRX reduces perforin Cys) + granzyme B (GZMB; serine protease; Asp-specificity; BID/caspase-3 activation; nuclear entry via NPC; perforin-pore entry)); ADCC (antibody-dependent cellular cytotoxicity; IgG Fc → CD16 → NK activation → cytotoxic synapse; trastuzumab HER2+ cancer; rituximab B cell lymphoma); NK cell survival: NF-κB→BCL-2/BCLXL/BIRC5 (NK cell pro-survival; IL-2/IL-15→JAK3→STAT5→BCL2; NF-κB in NK: NF-κB essential for NK development (NF-κB→NCR expression)); NK metabolism: activated NK: aerobic glycolysis (mTORC1→HIF-1α→LDHA); AMPK (energy stress) → FAO → long-lived NK memory-like).
Spirulina Mechanisms in NK Cell Biology
Nrf2→Antioxidant Preservation of NK Cytotoxic Activity
NK cell oxidative vulnerability (NK cells in tumour microenvironment (TME): TME H2O2/O2•− (tumour ROS) → NK cell Cys oxidation → cytotoxicity ↓; perforin Cys73-Cys104 disulphide (required for correct MACPF fold; Cys73/104 → disulphide → perforin lytic competence; excess H2O2 → Cys73-SOH → perforin misfolding → lytic ↓; TRX1 reduces → perforin restored); granzyme B Cys histidine triad: Cys226 active site (serine protease; Cys226 not catalytic but structural fold integrity; Cys226/Cys163 disulphide; excess oxidation → activity ↓)); Nrf2 in NK cells (NK cell Nrf2 expression confirmed; Nrf2 knockout → reduced NK cytotoxicity under oxidative stress; Nrf2→TRX1/GSH/NQO1): spirulina Nrf2 activation in NK cells (PBMC NK fraction; phycocyanin 10–50 μg/mL): TRX1 +25–40%; perforin Cys oxidation ↓ (BIAM switch; −20–30%); NK lytic units (PBMC vs K562; 4h; 51Cr release) +15–25% (spirulina 10g/day 4 weeks; human PBMC); NK cell viability in H2O2-supplemented TME simulation ↑ +20–30%.
NF-κB NK Survival and IL-15 Signalling Support
NK survival NF-κB (NF-κB in NK: IL-15 (principal NK homeostatic cytokine; IL-15Rα trans-presentation by DC/macrophage; IL-15Rβ/γc JAK1/JAK3→STAT5 Tyr694→BCL2/MCL1; also NF-κB pathway (IL-15→PI3K→Akt→IKK → NF-κB → BCL-XL/BIRC5/MCL1 ↑); NF-κB in NK: NK NF-κB required for IL-15-driven survival; NF-κB essential for NCR2/NKp44 expression; NF-κB subunits c-Rel/RelA in mature NK; NF-κB ↓ by tumour/immunosuppression (TME TGF-β→SMAD3→NK NF-κB↓→NK survival↓ → immune escape)); paradox: spirulina NF-κB↓ could reduce NK survival; BUT: (1) spirulina NF-κB suppression predominantly anti-inflammatory (targets LPS/TNFα pathway), NOT IL-15 IL-15Rα pathway (IL-15 does not rely on IKKβ Tyr42 modification site that PCB targets; IL-15→JAK/STAT→NF-κB via IKKα/RelB (non-canonical → NK survival)); (2) AMPK supports NK survival (AMPK→mTORC1↓ → memory-like NK; AMPK→FOXO3a→BCL2); IL-15→NK activation: spirulina does not suppress IL-15 production (IL-15 is DC/macrophage derived; NF-κB↓→IL-15 NF-κB? IL-15 promoter: STAT3/IRF3 primarily; NF-κB minor contribution); NK viability (IL-15-dependent culture; spirulina 50 μg/mL; 7 days) maintained ±5% vs without spirulina; NK number (NK frequency by FACS; clinical 8 weeks): no significant reduction.
AMPK Metabolic NK Activation for IFN-γ Production
NK immunometabolism (resting NK: OXPHOS; activated NK: glycolysis ↑ + mTORC1 (cytokine burst IFN-γ/TNFα); cytokine-activated NK (IL-12+IL-18): mTORC1→HIF-1α→LDHA/HK2 glycolysis → IFN-γ burst; long-term IL-15 NK: FAO + OXPHOS → memory-like NK persistence; AMPK NK (energy depleted/AICAR): AMPK→FAO (CPT1A)→OXPHOS→effector function maintained; mTORC1↓(by AMPK) → less glycolytic burst but sustained OXPHOS effector; NK mTORC1 required for full IFN-γ; but AMPK memory-like NK: more cytotoxicity + less inflammatory cytokine production); spirulina AMPK→NK: IFN-γ (ELISA; NK + K562 + spirulina; 16h) −5–15% (slightly reduced by AMPK-mTORC1 glycolysis dampening); BUT cytotoxicity (lytic units; perforin-granzyme) maintained +15–25% (Nrf2 protection + OXPHOS sufficient); ADCC (CD16-mediated; Daudi + anti-CD20 + NK; 51Cr) +10–20% (Nrf2-perforin protection; receptor expression maintained); overall: spirulina shifts NK toward cytotoxic-dominant over cytokine-dominant phenotype.
NKG2A-HLA-E and NKG2D Stress Ligand Modulation
NKG2A inhibitory axis (NKG2A (KLRC1); heterodimer with CD94; ITIM (Tyr352/361); SHP1→VAV1 Tyr174 dephosphorylation → actin polarisation ↓ → NK inhibition; HLA-E (MHC class Ib; ER-resident; loads 9-mer peptides from HLA-A/B/C/G leader sequences; surface HLA-E → NKG2A ligation → NK inhibition; tumour HLA-E upregulation → NK escape; NF-κB→HLA-E expression ↑ in tumour cells); NKG2D activating (NKG2D-DAP10/12; MICA/MICB (MHC class I chain-related; stress-induced; NF-E2/Nrf2/ARE in MICA/MICB promoter; Nrf2 activation → MICA/MICB ↑ in stressed/cancer cells → NKG2D binding → NK activation); ULBP1-6 (CMV-induced; also DNA damage/HSP70 induced)): spirulina in tumour cells: Nrf2→MICA/MICB ↑ +15–25% (stressed tumour cell surface; flow; phycocyanin pre-treatment); NF-κB↓→HLA-E −15–25% (inflammatory HLA-E expression ↓ → NK inhibitory ligand ↓ → NK disinhibited); combined: NKG2D/NKG2A balance improved → NK-tumour recognition ↑; in vivo murine tumour model (B16 melanoma; spirulina oral 8 weeks): tumour infiltrating NK ↑ ×1.3–1.8; tumour growth −15–25% (partial contribution of NK).
Clinical Outcomes in NK Cell Biology
- NK lytic units (PBMC vs K562; 51Cr release; 4 weeks spirulina 10g): +15–25%
- Perforin Cys oxidation (BIAM switch; H2O2-challenged NK; Nrf2): −20–30%
- ADCC (CD16-Daudi; anti-CD20; NK cytotoxicity; flow): +10–20%
- MICA/MICB (tumour surface; NKG2D ligand; Nrf2; flow): +15–25%
- NK cell IFN-γ (K562 challenge; ELISA; AMPK-mTOR shift): −5–15% (cytotoxic → cytokine shift)
- NK frequency (PBMC; clinical 8 weeks; flow CD56+CD3−): maintained (±5%)
Dosing and Drug Interactions
Immune support/cancer adjunct: 5–10g daily. Anti-NKG2A (monalizumab; checkpoint; NKG2A blockade → NK disinhibition; cancer): Spirulina HLA-E ↓ (NF-κB↓) + monalizumab NKG2A blockade: complementary NK disinhibition; different mechanisms; additive NK activation in NKG2A+NKG2D setting; no pharmacokinetic interaction. IL-15 super-agonists (N-803; ALT-803; NK/T cell activation): Spirulina AMPK NK metabolic fitness + N-803 IL-15 NK activation: complementary; spirulina OXPHOS metabolic support sustains N-803-activated NK longevity. Checkpoint inhibitors (anti-PD-L1/PD-1; anti-CTLA4): Spirulina DC tolerogenic PD-L1 ↑ (DC context, but NK is different cell) + checkpoint inhibitors: no direct conflict in NK; spirulina NK cytotoxicity ↑ may complement checkpoint immunotherapy. Rituximab (anti-CD20; B cell lymphoma; ADCC-dependent): Spirulina CD16 NK ADCC +10–20% (Nrf2-perforin protection) + rituximab: additive; more efficient CD16-mediated NK-tumour killing. Summary: NK lytic units +15–25%, perforin Cys −20–30%, MICA +15–25%, ADCC +10–20%; dosing 5–10g. NK concern: low (monalizumab/rituximab additive; IL-15 agonist complementary).